News

A man with rheumatoid arthritis and cold agglutinin disease (CAD) achieved complete remission following treatment with rituximab, an antibody-based therapy commonly used off-label for CAD, a recent case study indicates. Rituximab therapy also treated the man’s cooccurring immune thrombocytopenia, an autoimmune disorder marked by the destruction of platelets, which…

A Japanese man with severe anemia — a condition marked by too few red blood cells in the body — following a case of COVID-19 tested positive for cold agglutinins and cryoglobulins, two types of antibodies that become reactive in the cold, according to a new report. Cold agglutinins are…

Very low doses of rituximab rapidly reduced blood levels of disease-driving B-cells in people with cold agglutinin disease (CAD) and other forms of autoimmune hemolytic anemia (AIHA), but this suppression was not consistently sustained over time. Those are the findings of a small pilot Phase 2 clinical…

Warming and an extra dose of corticosteroid medication were part of multiple strategies doctors used to allow for a safe Cesarean section (c-section), without complications, in a pregnant woman with cold agglutinin disease (CAD), according to a case report. The woman was kept warm right during her hospital stay,…

Cold agglutinin disease (CAD) was the likely trigger of repeated mini-strokes in an 84-year-old woman with already compromised blood flow in the brain due to severe narrowing of a major artery that supplies blood to the brain, according to a case report from Portugal. The underlying mechanisms of red…

Researchers said a case of cold agglutinin disease (CAD) in a 92-year-old man in Pakistan illustrates the challenges of CAD diagnosis and management in developing countries. The man’s experience highlights “the urgent need to improve healthcare infrastructure and enhance diagnostic capabilities while facilitating equitable access to essential CAD treatments…

The results from Annexon Biosciences‘ ongoing proof-of-concept clinical trial of ANX1502, its novel treatment candidate for cold agglutinin disease (CAD), are now expected in early 2025, the company has announced. That trial is testing a new tablet formulation of the oral therapy in people with CAD. Earlier this…

Treatment with rituximab — commonly used off-label for cold agglutinin disease (CAD) — was reported to successfully resolve a serious case of CAD secondary to an Epstein-Barr virus (EBV) infection and potential contraceptive pill toxicity in a young woman in Europe. The woman had developed severe jaundice and liver…

Establishing a diagnosis of autoimmune hemolytic anemia (AIHA), a group of conditions including cold agglutinin disease (CAD), is sometimes difficult, due to the high variability in signs and symptoms and the possibility of a secondary cause, a review study showed. “Additionally, therapy is poorly evidence-based and mainly funded on…

Zydus Lifesciences’ desidustat eases the anemia and red blood cell destruction that mark autoimmune hemolytic anemia, or AIHA, a group of autoimmune conditions that includes cold agglutinin disease (CAD), a study in a mouse model has found. The oral therapy was shown to stimulate red blood cell production…